PAC1R antagonist (Amgen Inc)

N/A

Report date: 2025/11/26 14:00:57
NME

Base Information

Drug NamePAC1R antagonist (Amgen Inc)
Drug Alias NamePAC1R antagonist (Amgen Inc)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide type I receptor antagonists
TargetsPituitary adenylate cyclase-activating polypeptide type I receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A